Clinical Trial Update: A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors [Phase 1]

View source ↗

Summary

This clinical trial update describes an ongoing Phase 1 study evaluating the recombinant oncolytic virus M1 (VRT106) in patients with solid tumors, sponsored by…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• M1 (VRT106)

Snippet

Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd. | Conditions: Solid Tumor | Phase 1 | Status: RECRUITING